Tom reports and edits European consumer health care industry news and analysis. Leading HBW Insight’s health and wellness coverage in Europe, he has been writing about the sector since 2013. Tom’s main focus is analyzing the strategies of the world's leading consumer healthcare companies, their business performance, plans and product portfolios. He also reports on regulatory topics such as novel foods and prescription-to-OTC switches.
Latest from Tom Gallen
A round-up of the latest European people moves: PAGB names new president; Enzymatica hires marketing & sales director; Marinomed strengthens supervisory board.
Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.
Now backed by private-equity firm 21 Invest, Omega Pharma is bolstering its Italian nutraceutical portfolio through the acquistion of Inpha and its Normocis brand.
Australian government finds an insufficient body of new evidence to support Rx-to-OTC switch of erectile dysfunction drug sildenafil since it was last considered in 2020.
Offer valuing struggling UK consumer health player Alliance at £350m has the backing of the company's board of directors.
Deal for fellow Belgian firm Kela will bolster Ceres' consumer health offering in Europe with brands such as Folavit and Hyalo.